Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab

13:37
 
Share
 

Manage episode 470784120 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Audio Journal of Oncology

Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab

LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-1) agent pembrolizumab resulted in markedly high melanoma-specific survival rates among patients with either resectable or metastatic desmoplastic melanoma in a study reported to the American Association for Cancer Research 2025 Immno Oncology conference.

Lead researcher Kari L Kendra MD PhD, Director of the Cutaneous Oncology Program and Chair of the Melanoma Disease Specific Committee at Ohio State University’s Wexner Medical Center in Columbus, OH gave the Audio Journal of Oncology’s Peter Goodwin the latest details:

  continue reading

51 episodes

Artwork
iconShare
 
Manage episode 470784120 series 1256601
Content provided by Audio Medica News. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audio Medica News or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Audio Journal of Oncology

Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab

LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-1) agent pembrolizumab resulted in markedly high melanoma-specific survival rates among patients with either resectable or metastatic desmoplastic melanoma in a study reported to the American Association for Cancer Research 2025 Immno Oncology conference.

Lead researcher Kari L Kendra MD PhD, Director of the Cutaneous Oncology Program and Chair of the Melanoma Disease Specific Committee at Ohio State University’s Wexner Medical Center in Columbus, OH gave the Audio Journal of Oncology’s Peter Goodwin the latest details:

  continue reading

51 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play